- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04301843
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Study Overview
Detailed Description
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.
Subjects will be evaluated in 3 arms:
• Arm 1: Subjects who show no active disease after receiving any additional therapy for neuroblastoma that was refractory to standard induction/consolidation therapy.
Refractory: Subjects with progressive disease on upfront therapy OR did not have at least PR on induction OR required additional second line therapy to achieve remission who are now in first remission.
- Arm 2: Subjects who have previously relapsed and currently show no active disease (in CR2 or greater).
- Arm 3: Subjects who are relapsed or refractory with active disease.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Expanded Access
Contacts and Locations
Study Contact
- Name: Genevieve Bergendahl, MSN
- Phone Number: 7175310003
- Email: gbergendahl@pennstatehealth.psu.edu
Study Contact Backup
- Name: Abigail Moore
- Email: amoore13@pennstatehealth.psu.edu
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Recruiting
- CancerCare Manitoba
-
Contact:
- Krista Mueller
- Email: kmueller@cancercare.mb.ca
-
Principal Investigator:
- Issai Vanan, MD
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- Montreal Children's Hospital
-
Principal Investigator:
- Sharon Abish, MD
-
Contact:
- Dominique Lafreniere
- Email: Dominique.Lafreniere@MUHC.MCGILL.CA
-
Montréal, Quebec, Canada
- Recruiting
- UHC Sainte-Justine
-
Contact:
- Guillaume Leblanc
- Email: guillaume.leblanc.hsj@ssss.gouv.qc.ca
-
Principal Investigator:
- Pierre Tiera, MD
-
Quebec City, Quebec, Canada
- Recruiting
- CHUQ
-
Principal Investigator:
- Bruno Michon, MD
-
Contact:
- Valérie-Ève Julien
- Email: Valerie-Eve.Julien@crchudequebec.ulaval.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35201
- Recruiting
- University of Alabama, Children's Alabama
-
Contact:
- Jennifer Ward, MD
- Email: jennifer.ward@aah.org
-
Principal Investigator:
- Rebecca McFall, MD
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Recruiting
- Arkansas Children's Hospital
-
Principal Investigator:
- Kevin Bielamowicz, MD
-
Contact:
- Susan Hall
- Phone Number: 501-364-2760
- Email: HallSF@archildrens.org
-
-
California
-
Oakland, California, United States, 94609
- Recruiting
- UCSF Benioff Children's Hospital Oakland-
-
Contact:
- Group Contact
- Email: PedOncRschOAK@ucsf.edu
-
Principal Investigator:
- Jennifer Michlitsch, MD
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital
-
Principal Investigator:
- William Roberts, MD
-
Contact:
- Sherri Brandsen
- Phone Number: 858-966-8155
- Email: sbrandsen@rchsd.org
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Recruiting
- Connecticut Children's Hospital
-
Principal Investigator:
- Michael Isakoff, MD
-
Contact:
- Nicole McCracken
- Phone Number: 860-545-9337
- Email: NMccracken@connecticutchildrens.org
-
-
Florida
-
Orlando, Florida, United States, 32806
- Recruiting
- Arnold Palmer Hospital for Children
-
Principal Investigator:
- Amy Smith, MD
-
Contact:
- Michelle Pellet
- Phone Number: 321-841-8588
- Email: Michelle.Pellett@orlandohealth.com
-
Tampa, Florida, United States, 33614
- Recruiting
- St. Joseph's Children's Hospital
-
Principal Investigator:
- Don Eslin, MD
-
Contact:
- Jennifer Manns, RN
- Phone Number: 813-357-0849
- Email: jennifer.manns@baycare.org
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Augusta University Health
-
Contact:
- Kimberly Gray
- Email: kigray@augusta.edu
-
Principal Investigator:
- Coleen McDonough, MD
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Recruiting
- Kapiolani Medical Center for Women and Children
-
Contact:
- Andrea Siu, MPH
- Phone Number: 808-535-7169
- Email: andrea.siu@kapiolani.org
-
Principal Investigator:
- Randal Wada, MD
-
-
Kentucky
-
Louisville, Kentucky, United States, 40201
- Recruiting
- University of Louisville
-
Principal Investigator:
- Ashok Raj, MD
-
Contact:
- Jennifer Miller
- Email: Jennifer.Miller4@nortonhealthcare.org
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Helen DeVos Children's Hospital
-
Contact:
- Mary Beth Readwin
- Phone Number: 616-267-0334
- Email: mary.readwin2@corewellhealth.org
-
Principal Investigator:
- David Hoogstra, MD
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Children's Hospital and Clinics of Minnesota
-
Principal Investigator:
- Jawhar Rawwas, MD
-
Contact:
- Nel Siemsen
- Phone Number: 612-813-5913
- Email: Nel.Siemsen@childrensmn.org
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospitals and Clinics
-
Contact:
- Nicole Harvey
- Phone Number: 816-302-6893
- Email: ndharvey@cmh.edu
-
Principal Investigator:
- Kevin Ginn, MD
-
Saint Louis, Missouri, United States, 63104
- Recruiting
- Cardinal Glennon Children's Hospital
-
Principal Investigator:
- William Ferguson, MD
-
Contact:
- Gina Martin
- Phone Number: 314-268-4000
- Email: gina.martin@health.slu.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
Contact:
- Sherri Mayans
- Email: sherri.mayans@hmhn.org
-
Principal Investigator:
- Derek Hanson, MD
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Levine Children's Hospital
-
Contact:
- Jotnyce Green
- Phone Number: 980-442-2356
- Email: jontyce.green@atriumhealth.org
-
Principal Investigator:
- Thomas Russell, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Children's
-
Contact:
- Luba Platt
- Email: PLATTL@ccf.org
-
Principal Investigator:
- Stacey Zahler, MD
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Milton S. Hershey Medical Center and Children's Hospital
-
Contact:
- Suzanne Treadway
- Email: streadway@hmc.psu.edu
-
Principal Investigator:
- Valerie Brown, MD
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02901
- Recruiting
- Hasbro Children's Hospital
-
Contact:
- Christopher Bouressa
- Email: cbouressa@lifespan.org
-
Principal Investigator:
- Bradley DeNardo, MD
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Not yet recruiting
- Medical University of South Carolina
-
Principal Investigator:
- Jaqueline Kraveka, MD
-
Contact:
- Shanta Salzar, MD
- Phone Number: 843-792-2957
- Email: salzers@musc.edu
-
-
Texas
-
Austin, Texas, United States, 78723
- Recruiting
- Dell Children's Blood and Cancer Center
-
Principal Investigator:
- Virginia Harrod, MD
-
Contact:
- Rhea Robinson, RN
- Phone Number: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Dallas, Texas, United States, 75235
- Recruiting
- Children's Medical Center Dallas
-
Principal Investigator:
- Tanya Watt, MD
-
Contact:
- Caitlyn Ambrose
- Email: caitlyn.ambrose@childrens.com
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Recruiting
- Children's Hospital of The King's Daughters
-
Contact:
- Sabrina Wigginton
- Email: Sabrina.Wigginton@chkd.org
-
Principal Investigator:
- Eric Lowe, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Contact:
- Ashley Hain
- Email: ahain@childrenswi.org
-
Principal Investigator:
- Nathan Schloemer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients must have a pathologically confirmed diagnosis of neuroblastoma, ≤ 30.99 years of age with history of relapsed/refractory neuroblastoma.
- All patients must have completed upfront therapy with at least 4 cycles of aggressive multi-drug chemotherapy.
- Specific Criteria by Arm:
Arms 1 and 2:
Subjects with no active disease:
i. No evidence of residual disease by CT/MRI and MIBG scan (or PET for patients who have a history of MIBG non-avid disease).
o Note: Patients with residual masses detected by CT/MRI may be considered in CR if their MIBG is negative or if MIBG positive and evaluated by PET and found to have negative PET scans; biopsy confirmation may be considered if there is still reasonable concern for persistent disease but is not required.
ii. No evidence of disease metastatic to bone marrow.
Arm 3:
Measurable or evaluable disease, including at least one of the following:
Measurable tumor by CT or MRI; or a positive MIBG and PET; or positive bone marrow biopsy/aspirate in at least one site.
- Timing from prior therapy: Enrollment (first dose of DFMO) no later than 60 days from last dose of the most recent therapy.
Subjects must have fully recovered from the acute toxic effects of all prior anti- cancer chemotherapy and be within the following timelines:
- Myelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
- Hematopoietic growth factors: At least 5 days since the completion of therapy with a growth factor.
- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the Study Chair.
- Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines, CAR-T cells.
- Anti-GD2 Monoclonal antibodies: At least 2 weeks must have elapsed since prior treatment with a monoclonal antibody.
- XRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
Stem Cell Transplant:
- Allogeneic: No evidence of active graft vs. host disease
- Allo/Auto: ≥ 2 months must have elapsed since transplant.
- MIBG Therapy: At least 8 weeks since treatment with MIBG therapy
- Subjects must have a Lansky or Karnofsky Performance Scale score of 60% or higher.
- Life expectancy > 2 months
- All clinical and laboratory studies for organ functions to determine eligibility must be performed within 7 days prior to first dose of study drug unless otherwise indicated below.
Subjects must have adequate organ functions at the time of registration:
- Hematological: Total absolute neutrophil count ANC ≥750/μL
- Liver: Subjects must have adequate liver function as defined by AST and ALT <5x upper limit of normal (Normal=45), Bilirubin <1.5x upper limit normal (Normal=1.0). Normal PT, PTT, fibrinogen.
- Renal: Adequate renal function defined as (perform one of the following): Creatinine clearance or radioisotope GFR 70 mL/min/1.73 m2 or greater or a serum creatinine based on age/gender
- Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.
- Written informed consent in accordance with institutional and FDA guidelines must be obtained from all subjects (or patients' legal representative).
Exclusion Criteria:
- BSA of <0.25 m2.
- Subjects that received DFMO at a dose higher than 1000mg/m2 BID prior to this study are not eligible.
- Subjects that received a dose of DFMO in combination with etoposide are not eligible.
- Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
- Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from hematological and bone marrow suppression effects of prior chemotherapy.
- Infection: Subjects who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
- Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eflornithine (DFMO)
In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone. Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed. DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study. |
DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with event free survival (EFS) during study
Time Frame: 2 years plus 5 years follow up
|
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Event free survival (EFS) from time of enrollment. |
2 years plus 5 years follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of time that participants experience Overall Survival (OS)
Time Frame: 7 years
|
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Overall Survival (OS) from time of enrollment. |
7 years
|
Determine the Overall Response Rate (ORR) of Participants using INSS Response Evaluation Criteria.
Time Frame: 2 years
|
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Response Rate for patients with active disease (Arm 3) using International Neuroblastoma Staging System (INSS) Response Evaluation Criteria. |
2 years
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 2 years plus 30 days
|
To monitor the safety and tolerability profile of difluoromethylornithine (DFMO) in combination with etoposide in pediatric and young adult patients with relapsed/refractory neuroblastoma.
|
2 years plus 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Giselle Sholler, MD, Beat Childhood Cancer
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroblastoma
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Trypanocidal Agents
- Ornithine Decarboxylase Inhibitors
- Eflornithine
Other Study ID Numbers
- BCC015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroblastoma
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 NeuroblastomaUnited States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S NeuroblastomaUnited States
Clinical Trials on Eflornithine
-
Orbus Therapeutics, Inc.RecruitingGlioblastoma | Glioblastoma Multiforme | GBM | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeUnited States
-
Walter Reed National Military Medical CenterTerminatedPseudofolliculitis BarbaeUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.Active, not recruiting
-
National Cancer Institute (NCI)Completed
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNon-melanomatous Skin Cancer
-
Hordinsky, Maria K., MDCompletedPseudofolliculitis BarbaeUnited States
-
Giselle ShollerBeat NB Cancer Foundation; Team Parker for LifeRecruiting
-
Thomas E. AhleringNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Bispebjerg HospitalCompleted